2023. A Case Report on Prolonged Response with Trastuzumab Emtansine (T-DM1) in Recurrent Advance Breast Cancer Setting. Journal of Cancer Research Updates. 12, (Dec. 2023), 49–53. DOI:https://doi.org/10.30683/1929-2279.2023.12.9.